Fotios Loupakis

List of Publications by Year
in descending order

352 papers	16,972 citations	20759 60 h-index	17546 121 g-index
361 all docs	361 docs citations	361 times ranked	19752 citing authors

#	Article	IF	Citations
1	Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 2013, 10, 472-484.	12.5	1,482
2	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
3	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
4	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	5.1	835
5	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	15.2	809
6	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	2.9	509
7	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
8	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	385
9	Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 2019, 51, 1113-1122.	9.4	315
10	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	0.8	254
11	Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. Journal of Clinical Oncology, 2007, 25, 1247-1254.	0.8	250
12	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	5.1	234
13	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234
14	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	2.9	226
15	High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. Oncologist, 2008, 13, 1270-1275.	1.9	218
16	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. Annals of Surgery, 2009, 249, 420-425.	2.1	213
17	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196
18	Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence. Clinical Cancer Research, 2012, 18, 645-653.	3.2	173

#	Article	IF	Citations
19	Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. British Journal of Cancer, 2009, 100, 881-887.	2.9	164
20	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 57-63.	1.3	162
21	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open, 2020, 5, e000759.	2.0	161
22	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. Journal of the National Cancer Institute, 2011, 103, 21-30.	3.0	160
23	Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2006, 13, 58-65.	0.7	156
24	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Annals of Oncology, 2015, 26, 1188-1194.	0.6	153
25	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. British Journal of Cancer, 2015, 112, 1921-1928.	2.9	146
26	First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
27	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	0.6	137
28	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Annals of Oncology, 2015, 26, 724-730.	0.6	136
29	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
30	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
31	Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1427-1434.	0.8	124
32	Nuclear Factor-ĸB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. Journal of Clinical Oncology, 2007, 25, 3930-3935.	0.8	121
33	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	0.8	116
34	Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell International, 2019, 19, 209.	1.8	116
35	TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treatment Reviews, 2015, 41, 777-783.	3.4	115
36	Influence of Sex on the Survival of Patients With Esophageal Cancer. Journal of Clinical Oncology, 2012, 30, 2265-2272.	0.8	112

#	Article	IF	Citations
37	Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan. Pharmacogenomics Journal, 2010, 10, 458-464.	0.9	109
38	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics Journal, 2008, 8, 278-288.	0.9	97
39	Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Annals of Oncology, 2010, 21, 2382-2389.	0.6	94
40	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With *RAS* and *BRAF* Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
41	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	2.9	93
42	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
43	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq1 1 0.784314 rgBT /Overlo Nord Ovest (GONO). Annals of Oncology, 2013, 24, 2062-2067.	0.6	86
44	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. British Journal of Cancer, 2011, 104, 1262-1269.	2.9	85
45	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	1.4	85
46	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Annals of Oncology, 2018, 29, 1528-1534.	0.6	83
47	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Annals of Oncology, 2012, 23, 135-141.	0.6	79
48	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics Journal, 2017, 17, 258-264.	0.9	79
49	Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. Oncology, 2010, 79, 187-196.	0.9	77
50	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	1.9	77
51	Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Safety, 2019, 42, 211-233.	1.4	76
52	High Let-7a MicroRNA Levels in *KRAS*-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. Oncologist, 2012, 17, 823-829.	1.9	74
53	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69
54	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World Journal of Gastroenterology, 2019, 25, 5773-5788.	1.4	69

#	Article	IF	Citations
55	Insulinâ€like growth factor 1 expression correlates with clinical outcome in Kâ€RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	2.3	67
56	Class 1, 2, and 3 <i>BRAF</i>-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67
57	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer, 2009, 9, 303.	1.1	66
58	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
59	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology, 2019, 37, 3099-3110.	0.8	65
60	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	1.1	64
61	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer, 2008, 98, 1312-1319.	2.9	63
62	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	1.8	63
63	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis, 2012, 15, 275-286.	3.7	61
64	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	2.0	61
65	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	1.5	61
66	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. Journal of Clinical Oncology, 2007, 25, 1816-1818.	0.8	56
67	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	2.9	56
68	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nature Communications, 2018, 9, 4112.	5.8	55
69	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precision Oncology, 2021, 5, 1166-1177.	1.5	55
70	Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Annals of Oncology, 2011, 22, 1141-1146.	0.6	54
71	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	1.3	54
72	PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers, 2019, 11, 1765.	1.7	54

#	Article	IF	Citations
73	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 2019, 121, 257-263.	2.9	53
74	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. British Journal of Cancer, 2013, 108, 2549-2556.	2.9	51
75	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
76	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. European Journal of Cancer, 2019, 118, 121-130.	1.3	51
77	VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. International Journal of Colorectal Disease, 2009, 24, 165-170.	1.0	47
78	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental and Clinical Cancer Research, 2010, 29, 58.	3.5	46
79	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology, 2016, 27, 843-849.	0.6	46
80	FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.. Journal of Clinical Oncology, 2013, 31, 3505-3505.	0.8	46
81	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	0.8	46
82	Caveolin‐1 is a novel regulator of K‐RAS‐dependent migration in colon carcinogenesis. International Journal of Cancer, 2013, 133, 43-57.	2.3	45
83	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clinical Colorectal Cancer, 2020, 19, 219-225.	1.0	45
84	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 2017, 28, 555-561.	0.6	43
85	Single-Agent Panitumumab in Frail Elderly Patients With Advanced *RAS* and *BRAF* Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist, 2015, 20, 1261-1265.	1.9	42
86	Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. Journal of Personalized Medicine, 2021, 11, 1095.	1.1	42
87	Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics Journal, 2015, 15, 354-362.	0.9	41
88	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	3.2	41
89	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	1.1	41
90	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40

#	Article	IF	Citations
91	LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding RNA Research, 2018, 3, 195-212.	2.4	39
92	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Annals of Oncology, 2010, 21, 1565.	0.6	38
93	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine, 2019, 45, 139-154.	2.7	36
94	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics Journal, 2019, 19, 556-563.	0.9	35
95	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4001-4001.	0.8	35
96	Analysis of HER-3, insulin growth factor-1, nuclear factor-ĸB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecanâ€"cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	0.6	34
97	Clinical impact of antiâ€epidermal growth factor receptor monoclonal antibodies in firstâ€line treatment of metastatic colorectal cancer. Cancer, 2012, 118, 1523-1532.	2.0	34
98	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology, 2011, 78, 243-251.	2.0	31
99	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer, 2009, 100, 1720-1724.	2.9	30
100	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells, 2020, 9, 2019.	1.8	30
101	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	0.8	30
102	Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. British Journal of Cancer, 2008, 99, 716-721.	2.9	29
103	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Annals of Oncology, 2015, 26, 2450-2456.	0.6	29
104	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer, 2017, 116, 318-323.	2.9	29
105	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.	1.3	29
106	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. Clinical Colorectal Cancer, 2013, 12, 188-194.	1.0	28
107	Association of common gene variants in the WNT/Î²-catenin pathway with colon cancer recurrence. Pharmacogenomics Journal, 2014, 14, 142-150.	0.9	28
108	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of Oncology, 2017, 28, 2780-2785.	0.6	28

#	Article	IF	Citations
109	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer, 2017, 17, 408.	1.1	28
110	Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1187-1196.	1.2	27
111	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
112	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opinion on Biological Therapy, 2015, 15, 155-162.	1.4	27
113	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	0.8	26
114	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist, 2020, 25, 803-809.	1.9	26
115	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2015, 15, 69-76.	0.9	25
116	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	1.6	25
117	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clinical Colorectal Cancer, 2018, 17, e395-e414.	1.0	25
118	FOLFOXIRIÂplus bevacizumab (bev) versus FOLFIRIÂplus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	25
119	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	0.8	25
120	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Annals of Oncology, 2017, 28, 1015-1022.	0.6	24
121	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
122	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. British Journal of Cancer, 2019, 121, 593-599.	2.9	24
123	PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 151-156.	1.4	24
124	NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Modern Pathology, 2021, 34, 1547-1557.	2.9	24
125	Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics Journal, 2009, 9, 78-84.	0.9	23
126	CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine, 2016, 374, 2182-2184.	13.9	23

#	Article	IF	Citations
127	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research, 2018, 24, 784-793.	3.2	23
128	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
129	First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology, 2006, 17, 1249-1254.	0.6	22
130	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	6.1	22
131	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. European Journal of Cancer, 2017, 86, 197-206.	1.3	22
132	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	1.3	22
133	Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics Journal, 2014, 14, 14-19.	0.9	21
134	Prognostic Impact of *IL6* Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clinical Cancer Research, 2016, 22, 3218-3226.	3.2	21
135	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	1.4	21
136	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. Anticancer Research, 2017, 37, 315-320.	0.5	21
137	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clinical Colorectal Cancer, 2020, 19, 191-199.e6.	1.0	20
138	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. European Journal of Cancer, 2013, 49, 1501-1508.	1.3	19
139	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	1.9	19
140	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
141	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	2.9	19
142	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. European Journal of Cancer, 2020, 133, 66-73.	1.3	19
143	Palliative treatment of unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 63-77.	0.9	18
144	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of Oncology, 2015, 26, 2503.	0.6	18

#	Article	IF	Citations
145	A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Targeted Oncology, 2016, 11, 293-308.	1.7	18
146	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	1.0	18
147	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. Drug Safety, 2019, 42, 159-179.	1.4	18
148	Should Oncologists Be Aware in Their Clinical Practice of *KRAS* Molecular Analysis?. Journal of Clinical Oncology, 2011, 29, e206-e207.	0.8	17
149	The possible role of chemotherapy in antiangiogenic drug resistance. Medical Hypotheses, 2012, 78, 646-648.	0.8	17
150	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
151	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 98.	1.1	17
152	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
153	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. European Journal of Cancer, 2022, 166, 165-175.	1.3	17
154	Practical considerations in the use of regorafenib in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095686.	1.4	16
155	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 7-14.	1.0	15
156	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 945-949.	1.4	15
157	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 965-969.	1.1	15
158	Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics Journal, 2015, 15, 226-234.	0.9	14
159	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	2.0	14
160	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochemical Pharmacology, 2019, 164, 94-105.	2.0	14
161	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
162	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. International Journal of Cancer, 2020, 147, 2303-2315.	2.3	14

#	Article	IF	Citations
163	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics, 2008, 9, 55-69.	0.6	12
164	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. Current Cancer Drug Targets, 2010, 10, 37-45.	0.8	12
165	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	1.1	12
166	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer, 2018, 17, e471-e488.	1.0	12
167	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clinical Colorectal Cancer, 2019, 18, e8-e19.	1.0	12
168	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2017, 49, 834-845.	1.3	12
169	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Current Opinion in Oncology, 2008, 20, 459-465.	1.1	11
170	Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics, 2011, 12, 1077-1080.	0.6	11
171	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. Pharmacogenomics Journal, 2014, 14, 135-141.	0.9	11
172	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics Journal, 2014, 14, 322-327.	0.9	11
173	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2015, 372, 290-292.	13.9	11
174	BRAF-mutated metastatic colorectal cancer between past and future. British Journal of Cancer, 2015, 113, 1634-1635.	2.9	11
175	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology, 2016, 9, 877-885.	1.3	11
176	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics Journal, 2017, 17, 543-550.	0.9	11
177	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. Cancers, 2020, 12, 2049.	1.7	11
178	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
179	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics Journal, 2017, 17, 331-336.	0.9	10
180	Single nucleotide polymorphisms in the IGF–IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE–3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10

#	ARTICLE	IF	CITATIONS
181	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
182	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
183	Pharmacokinetics, a main actor in a manyâ€sided approach to severe 5â€FU toxicity prediction. British Journal of Clinical Pharmacology, 2009, 67, 132-134.	1.1	9
184	Clinical Significance of <i>TLR1</i> I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Molecular Cancer Therapeutics, 2016, 15, 1740-1745.	1.9	9
185	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	1.3	9
186	Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology, 2014, 32, 3519-3519.	0.8	9
187	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in <i>RAS</i>/<i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. Journal of Clinical Oncology, 2016, 34, 3543-3543.	0.8	9
188	Biomarkers and Response to Bevacizumabâ€"Letter. Clinical Cancer Research, 2014, 20, 1056-1057.	3.2	8
189	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology, 2017, 71, 1008-1011.	1.6	8
190	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
191	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Investigational New Drugs, 2018, 36, 709-714.	1.2	8
192	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
193	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patientsâ€™ Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.4	8
194	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. European Journal of Cancer, 2021, 146, 145-154.	1.3	8
195	Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum).. Journal of Clinical Oncology, 2013, 31, 3527-3527.	0.8	8
196	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. Journal of Clinical Oncology, 2015, 33, 3510-3510.	0.8	8
197	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 167-181.	1.4	7
198	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Annals of Oncology, 2012, 23, 1370-1371.	0.6	7

#	Article	IF	Citations
199	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	0.8	7
200	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. Annals of Oncology, 2016, 27, vi560.	0.6	7
201	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. Pharmacogenomics, 2017, 18, 197-200.	0.6	7
202	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	1.8	7
203	Noninferiority of three monthsversussix months of oxaliplatinâ€based adjuvant chemotherapy for resected colon cancer. How shouldIDEAfindings affect clinical practice?. International Journal of Cancer, 2018, 143, 2342-2350.	2.3	7
204	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. Expert Review of Respiratory Medicine, 2019, 13, 635-644.	1.0	7
205	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318.	1.4	7
206	Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1897-1904.	1.2	7
207	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	1.7	7
208	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics, 2010, 11, 1247-1256.	0.6	6
209	Ramucirumab: the long and winding road toward being an option for mCRC treatment. Expert Opinion on Biological Therapy, 2019, 19, 399-409.	1.4	6
210	Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 3540-3540.	0.8	6
211	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	0.8	6
212	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3524-3524.	0.8	6
213	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. Cancers, 2021, 13, 5128.	1.7	6
214	Refractory neuroendocrine tumorâ€"response to liposomal doxorubicin and capecitabine. Nature Reviews Clinical Oncology, 2009, 6, 670-674.	12.5	5
215	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2010, 66, 559-566.	1.1	5
216	Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. Annals of Oncology, 2010, 21, 181.	0.6	5

#	Article	IF	Citations
217	PML as a potential predictive factor of oxaliplatin/fluoropyrimidineâ€based first line chemotherapy efficacy in colorectal cancer patients. Journal of Cellular Physiology, 2012, 227, 927-933.	2.0	5
218	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. Annals of Oncology, 2013, 24, iv21.	0.6	5
219	<i>Topoisomerase 1</i> Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. Oncology, 2016, 91, 283-288.	0.9	5
220	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
221	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. Pharmacogenomics Journal, 2019, 19, 455-464.	0.9	5
222	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 2020, 15, e0239439.	1.1	5
223	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. Gastric Cancer, 2020, 23, 1064-1074.	2.7	5
224	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	1.6	5
225	CDX2 as a Prognostic Biomarker in Colon Cancer. New England Journal of Medicine, 2016, 374, 2183.	13.9	5
226	Optimal approach to potentially resectable liver metastases from colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1533-1539.	1.1	4
227	Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting â€œLost in TranslationALâ€?. Journal of Clinical Oncology, 2010, 28, e173-e174.	0.8	4
228	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics, 2015, 14, 2374-2381.	1.9	4
229	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. Tumori, 2016, 102, 108-113.	0.6	4
230	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. European Journal of Cancer, 2019, 111, 138-147.	1.3	4
231	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A metaâ€analysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	2.3	4
232	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2947.	1.7	4
233	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
234	Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 3613-3613.	0.8	4

#	Article	IF	Citations
235	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology, 2014, 32, 3596-3596.	0.8	4
236	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Journal of Clinical Oncology, 2018, 36, 3590-3590.	0.8	4
237	Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 726-726.	0.8	4
238	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. Journal of Clinical Oncology, 2019, 37, 558-558.	0.8	4
239	Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. BMC Gastroenterology, 2022, 22, 17.	0.8	4
240	How useful is adjuvant irinotecan in stage IV CRC?. Nature Reviews Clinical Oncology, 2010, 7, 190-191.	12.5	3
241	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3
242	Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'. British Journal of Cancer, 2013, 109, 3129-3130.	2.9	3
243	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. Annals of Oncology, 2016, 27, vi152.	0.6	3
244	The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. Annals of Oncology, 2018, 29, v82.	0.6	3
245	Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. BioMed Research International, 2018, 2018, 1-2.	0.9	3
246	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. Oncologist, 2019, 24, e77-e79.	1.9	3
247	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics Journal, 2021, 21, 285-295.	0.9	3
248	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. Scientific Reports, 2021, 11, 12191.	1.6	3
249	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 939-944.	1.4	3
250	Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3579-3579.	0.8	3
251	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. Journal of Clinical Oncology, 2019, 37, 3145-3145.	0.8	3
252	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. Journal of Clinical Oncology, 2018, 36, 662-662.	0.8	3

#	Article	IF	Citations
253	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103646.	2.0	3
254	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2022, 172, 22-30.	1.3	3
255	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. European Journal of Cancer, Supplement, 2008, 6, 86-90.	2.2	2
256	Do we need biopsies of metastases for colorectal cancer patients?. British Journal of Cancer, 2009, 101, 374-375.	2.9	2
257	Selecting the best targeted agent in first‑line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 528-535.	1.4	2
258	Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono. Annals of Oncology, 2013, 24, iv22.	0.6	2
259	Response. Journal of the National Cancer Institute, 2015, 107, djv205.	3.0	2
260	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. Pharmacogenomics Journal, 2015, 15, 235-240.	0.9	2
261	QoL is a cool tool. Annals of Oncology, 2017, 28, 2032-2033.	0.6	2
262	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 2019, 18, 245-256.e5.	1.0	2
263	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. Tumori, 2021, 107, 46-54.	0.6	2
264	Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.. Journal of Clinical Oncology, 2013, 31, e14577-e14577.	0.8	2
265	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664.	0.8	2
266	Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.. Journal of Clinical Oncology, 2014, 32, 521-521.	0.8	2
267	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3532-3532.	0.8	2
268	Genetic variants of <i>hENT-1</i> to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3580-3580.	0.8	2
269	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	0.8	2
270	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool"platform.. Journal of Clinical Oncology, 2018, 36, 639-639.	0.8	2

#	Article	IF	Citations
271	Correlation of messenger RNA expression patterns of ERCC1, TS, EGFR, and VEGFR2 with KRAS and BRAF mutational status in advanced colorectal cancer: Implications for targeted therapies.. Journal of Clinical Oncology, 2013, 31, 383-383.	0.8	2
272	Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. British Journal of Cancer, 2010, 102, 1076-1077.	2.9	1
273	â€œHER Majesty's a Pretty Nice Girl but She Changes From Day to Dayâ€• Journal of Clinical Oncology, 2012, 30, 465-466.	0.8	1
274	Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy. Current Colorectal Cancer Reports, 2012, 8, 263-271.	1.0	1
275	Long-Survivors with Lung Metastases and Kras Mutations Have an Increased Risk to Develop Brain Metastases From Colorectal Cancer. Annals of Oncology, 2013, 24, iv15.	0.6	1
276	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Colorectal Cancer, 2013, 2, 411-417.	0.8	1
277	New perspectives for TAS-102: TASK successful?. Lancet Oncology, The, 2017, 18, 1139-1141.	5.1	1
278	Potential contribution of the study nurse to colorectal cancer (CRC) translational research. Annals of Oncology, 2017, 28, vi110.	0.6	1
279	Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients. Critical Reviews in Oncology/Hematology, 2021, 167, 103271.	2.0	1
280	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1
281	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer, 2021, 150, 133-142.	1.3	1
282	Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).. Journal of Clinical Oncology, 2012, 30, 3518-3518.	0.8	1
283	Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.. Journal of Clinical Oncology, 2013, 31, 382-382.	0.8	1
284	mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology, 2014, 32, 3640-3640.	0.8	1
285	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. Journal of Clinical Oncology, 2015, 33, 3552-3552.	0.8	1
286	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 595-595.	0.8	1
287	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. Journal of Clinical Oncology, 2016, 34, 3540-3540.	0.8	1
288	Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. Journal of Clinical Oncology, 2016, 34, 3590-3590.	0.8	1

#	Article	IF	Citations
289	Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. Journal of Clinical Oncology, 2017, 35, 615-615.	0.8	1
290	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. Journal of Clinical Oncology, 2018, 36, 645-645.	0.8	1
291	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 692-692.	0.8	1
292	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 393-393.	0.8	1
293	CCL2 polymorphism as a predictive marker for bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, e14556-e14556.	0.8	1
294	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 3048-3048.	0.8	1
295	Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials. Cancer Research, 2019, 79, 1342-1342.	0.4	1
296	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Research, 2015, 35, 2391-9.	0.5	1
297	Are Dose-Finding Studies Still Necessary When Targeted Therapy Is Associated With Chemotherapy?. Journal of Clinical Oncology, 2006, 24, 4668-4669.	0.8	0
298	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does â€œAdjuvantâ€•Chemotherapy Play a Role After Resection?. Annals of Surgery, 2009, 250, 655.	2.1	0
299	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
300	PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients. Annals of Oncology, 2012, 23, iv22.	0.6	0
301	P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV). Annals of Oncology, 2012, 23, iv105-iv106.	0.6	0
302	Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients. Annals of Oncology, 2013, 24, iv28.	0.6	0
303	Conference Scene: Annual Meeting of the American Society of Clinical Oncology. Colorectal Cancer, 2013, 2, 401-404.	0.8	0
304	TRIBE study: are all three cytotoxic drugs crucial? â€" Authors' reply. Lancet Oncology, The, 2015, 16, e578-e579.	5.1	0
305	First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. Annals of Oncology, 2018, 29, v106.	0.6	0
306	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. Annals of Oncology, 2019, 30, v226.	0.6	0

#	Article	IF	Citations
307	Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. Annals of Oncology, 2019, 30, v763-v764.	0.6	0
308	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0
309	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 476-476.	0.8	0
310	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
311	Association of the prognostic role of CXCR4/CXCL12 polymorphism with treatment outcomes after bevacizumab-based chemotherapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e22008-e22008.	0.8	0
312	High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5		
313	Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. Journal of Clinical Oncology, 2014, 32, 3571-3571.	0.8	0
314	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3537-3537.	0.8	0
315	Common genetic variants in genes involved in the Hippo pathway: Novel biomarkers in metastatic colorectal cancer patients treated with irinotecan plus cetuximab.. Journal of Clinical Oncology, 2014, 32, e14523-e14523.	0.8	0
316	Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV).. Journal of Clinical Oncology, 2014, 32, e14528-e14528.	0.8	0
317	Polymorphism of the chemokine CXCR4 to predict treatment benefit of first-line bevacizumab-based chemotherapy in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 635-635.	0.8	0
318	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2015, 33, 591-591.	0.8	0
319	Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. Journal of Clinical Oncology, 2015, 33, 621-621.	0.8	0
320	Effect of genetic variation on overall survival in a clinical trial of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 3562-3562.	0.8	0
321	Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.. Journal of Clinical Oncology, 2015, 33, 3554-3554.	0.8	0
322	Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC).. Journal of Clinical Oncology, 2015, 33, e14519-e14519.	0.8	0
323	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2015, 33, e22075-e22075.	0.8	0
324	Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. Journal of Clinical Oncology, 2015, 33, 3613-3613.	0.8	0

#	Article	IF	Citations
325	Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. , 2015, , .		0
326	Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.. Journal of Clinical Oncology, 2016, 34, e15054-e15054.	0.8	0
327	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2016, 34, TPS3629-TPS3629.	0.8	0
328	Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.. Journal of Clinical Oncology, 2016, 34, e15127-e15127.	0.8	0
329	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. Journal of Clinical Oncology, 2016, 34, TPS3627-TPS3627.	0.8	0
330	Genetic variants of <i>Pin1</i> to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 11589-11589.	0.8	0
331	Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests.. Journal of Clinical Oncology, 2016, 34, 3606-3606.	0.8	0
332	NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial.. Journal of Clinical Oncology, 2016, 34, 11597-11597.	0.8	0
333	Identifying SNPs associated with progression-free survival (PFS) and overall survival (OS) in patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using Random Survival Forests (RSF).. Journal of Clinical Oncology, 2016, 34, 3604-3604.	0.8	0
334	IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.. Journal of Clinical Oncology, 2016, 34, 11600-11600.	0.8	0
335	Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors. , 2016, , .		0
336	Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2017, 35, 11608-11608.	0.8	0
337	Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up.. Journal of Clinical Oncology, 2017, 35, e21654-e21654.	0.8	0
338	The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, 651-651.	0.8	0
339	Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. Journal of Clinical Oncology, 2018, 36, 663-663.	0.8	0
340	Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.. Journal of Clinical Oncology, 2018, 36, 646-646.	0.8	0
341	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. Journal of Clinical Oncology, 2018, 36, 636-636.	0.8	0
342	Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 12066-12066.	0.8	0

#	Article	IF	Citations
343	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 12098-12098.	0.8	0
344	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, e15578-e15578.	0.8	0
345	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. Journal of Clinical Oncology, 2018, 36, 3575-3575.	0.8	0
346	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
347	Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. , 2018, , .		0
348	Abstract 206: The Consensus Molecular Classification (CMS) of primary colorectal tumors and their matched liver metastasis: Investigating the concordance. , 2018, , .		0
349	Abstract 2614: Macrophage erythroblast attacher (MAEA) polymorphisms are associated with clinical outcome in TRIBE study mCRC patients treated with 5-fluorouracil/bevacizumab-based therapy. , 2018, , .		0
350	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. Journal of Clinical Oncology, 2019, 37, 594-594.	0.8	0
351	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 566-566.	0.8	0
352	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. Journal of Clinical Oncology, 2019, 37, 3545-3545.	0.8	0